Log in
Log in
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
Twitter Twitter
Facebook Facebook
Apple Apple     


Real-time Estimate Cboe BZX  -  02:34 2022-12-09 pm EST
7.530 USD   -4.44%
11/23Sutro Biopharma to Participate in Upcoming Investor Conferences
11/09Transcript : Sutro Biopharma, Inc. Presents at Credit Suisse 31st Annual Healthcare Conference, Nov-09-2022 08:35 AM
11/09HC Wainwright Cuts Price Target on Sutro Biopharma to $20 From $30, Affirms Buy Rating
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sutro Biopharma Achieves 'First in Human' Milestone in Cytokine Derivatives Collaboration with Merck

07/27/2022 | 10:13am EST

SOUTH SAN FRANCISCO, Calif. - Sutro Biopharma, Inc. ('Sutro' or the 'Company') (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), announced that the first patient has been dosed in a Phase 1 study of an investigational candidate resulting from the collaboration between Sutro and Merck, known as MSD outside the United States and Canada, for the development of a novel cytokine derivative therapeutic for the treatment of cancer. As a result of this milestone, Sutro will receive a $10 million payment from Merck.

'We are pleased with the progress of this next-generation biologic candidate, from discovery to clinical development for patients with advanced or metastatic solid tumors,' said Bill Newell, Chief Executive Officer of Sutro. 'This milestone reflects the strong synergistic collaboration between Merck's biological expertise in the field of immuno-oncology and Sutro's prowess in designing, engineering, and manufacturing complex biologics that incorporate site-specific conjugation. We are excited about the potential this therapeutic may have for cancer patients.'

Under the terms of the July 2018 collaboration agreement between Sutro and Merck, Sutro has been primarily responsible for preclinical research and development, as well as manufacturing, of cytokine derivatives utilizing Sutro's proprietary cell-free protein synthesis and site-specific conjugation platforms, XpressCF and Xpress CF+. Merck has exclusive worldwide rights to therapeutic candidates derived from the collaboration.

About Sutro Biopharma

Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Sutro has two wholly owned ADCs in the clinic-STRO-002, a folate receptor alpha (FolR?)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies. Additionally, Sutro is collaborating with Bristol Myers Squibb (BMS) on CC-99712, a BCMA-targeting ADC in the clinic for patients with multiple myeloma; with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the U.S. and Canada (EMD Serono), on M1231, a MUC1-EGFR bispecific ADC in clinical studies for patients with solid tumors, particularly non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma; with Merck, known as MSD outside of the United States and Canada, a biologic in clinical studies for the treatment of solid tumors; and with Astellas Pharma (Astellas) on a novel modality, immunostimulatory antibody-drug conjugates (iADCs). Sutro's platform technology also enabled the spin out of Vaxcyte (Nasdaq: PCVX) and the creation of VAX-24, a 24-valent pneumococcal conjugate vaccine in clinical studies for the prevention of invasive pneumococcal disease. Sutro's rational design and precise protein engineering has enabled six product candidates in the clinic. Follow Sutro on Twitter,?@Sutrobio, and at www.sutrobio.com to learn more about our passion for changing the future of oncology.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated preclinical and clinical development activities, timing of announcements of clinical results, potential benefits of STRO-002 and Sutro's other product candidates and platform, potential future milestone and royalty payments, and potential market opportunities for STRO-002 and Sutro's other product candidates. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although Sutro believes that the expectations reflected in such forward-looking statements are reasonable, Sutro cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Forward-looking statements are subject to risks and uncertainties that may cause Sutro's actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to Sutro's ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates and Sutro's ability to successfully leverage Fast Track designation, the market size for Sutro's product candidates to be smaller than anticipated, the impact of the COVID-19 pandemic on Sutro's business, clinical trial sites, supply chain and manufacturing facilities, Sutro's ability to maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, Sutro's ability to fund development activities and achieve development goals, Sutro's ability to protect intellectual property and Sutro's commercial collaborations with third parties and other risks and uncertainties described under the heading 'Risk Factors' in documents Sutro files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and Sutro undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.


Investor & Media

Annie J. Chang

Sutro Biopharma

T: (650) 801-5728

E: ajchang@sutrobio.com

Amy Bonanno

Solebury Trout

T: (914) 450-0349

E: abonanno@soleburytrout.com

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
MERCK KGAA 2.77% 180 Delayed Quote.-22.84%
SUTRO BIOPHARMA, INC. -4.31% 7.54 Delayed Quote.-47.04%
VAXCYTE, INC. -2.26% 42.975 Delayed Quote.84.83%
All news about SUTRO BIOPHARMA, INC.
11/23Sutro Biopharma to Participate in Upcoming Investor Conferences
11/09Transcript : Sutro Biopharma, Inc. Presents at Credit Suisse 31st Annual Heal..
11/09HC Wainwright Cuts Price Target on Sutro Biopharma to $20 From $30, Affirms Buy Rating
11/08Earnings Flash (STRO) SUTRO BIOPHARMA Reports Q3 Revenue $25.1M
11/08SUTRO BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and ..
11/08Sutro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months En..
11/08Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and S..
11/03Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology ..
11/02Sutro Biopharma to Participate in Upcoming Investor Conferences
10/24Sutro Biopharma, Inc. : Change in Directors or Principal Officers (form 8-K)
More news
Analyst Recommendations on SUTRO BIOPHARMA, INC.
More recommendations
Financials (USD)
Sales 2022 66,7 M - -
Net income 2022 -126 M - -
Net cash 2022 166 M - -
P/E ratio 2022 -3,15x
Yield 2022 -
Capitalization 453 M 453 M -
EV / Sales 2022 4,30x
EV / Sales 2023 7,14x
Nbr of Employees 259
Free-Float 94,3%
Duration : Period :
Sutro Biopharma, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUTRO BIOPHARMA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 9
Last Close Price 7,88 $
Average target price 21,38 $
Spread / Average Target 171%
EPS Revisions
Managers and Directors
William J. Newell President, Chief Executive Officer & Director
Edward C. Albini Chief Financial Officer & Secretary
Connie L. Matsui Chairman
Henry Heinsohn Vice President-Technology & Innovation
Trevor Hallam Chief Scientific Officer & President-Research
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-33.36%41 753
WUXI APPTEC CO., LTD.-32.50%33 492
GENMAB A/S23.08%29 964